World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Published By Datamonitor

Tarsa: Novartis's fracture data do not bode well for Ostora

Novartis's SMC021 has failed to meet its main fracture reduction endpoint in a Phase III trial for osteoporosis. This is a setback for other firms aiming to stimulate the class's growth, such as Tarsa, which may now struggle to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue the development of SMC021 and focus on more attractive targets for osteoporosis treatment.

Published By Datamonitor

Servier: new Protelos data highlight shifting focus in osteoporosis research

As one of the lead sponsors of this year's World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, Servier presented new data for its dual action drug Protelos. Discussion of the therapy led on to the importance of companies using bone quality assessment, rather than relying on measurements of bone mineral density.

Published By Datamonitor

Osteoporosis: market driven by pipeline products

Published By Datamonitor

Osteologix and Servier: promising outlook for bone drug candidate

Servier and Osteologix have entered into an agreement for the development and commercialization of Osteologix's novel dual acting bone agent for the treatment of osteoporosis, NBS101. While this partnership bodes well for the outlook of the drug in Europe, a medium or large US partner would unlock the treatment's true commercial potential.

Published By Datamonitor

Noven: Mesafem emerges as potential alternative to HRT

Recently announced results suggest that Noven's non-hormonal therapy Mesafem is effective in relieving vasomotor symptoms associated with the menopause. However, Datamonitor believes that Mesafem will have to demonstrate equivalent or superior efficacy to hormonal replacement therapy if it is to overcome the challenges in this underserved market.

Published By Datamonitor

HRT market: innovative treatment options to restore growth

Published By Datamonitor

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor

FIGO 2009: expert backing for HRT for menopausal symptoms is welcome news

The debate regarding the use of HRT in postmenopausal women and its safety was very much a central topic throughout this year's International Federation of Gynecology and Obstetrics conference. Despite market-leader Wyeth's absence from the meeting, the core message that HRT should continue to be given to women in need will benefit players in this market.

Published By Datamonitor

FIGO 2009: Bayer-Schering maintains leadership in contraception

Datamonitor attended this year's International Federation of Gynecology and Obstetrics World Congress in Cape Town to assess the state of the women's healthcare market. The overwhelming presence of Bayer-Schering at the conference confirms the company's strength in the contraceptives field and its commitment to maintaining its market-leading position.

Published By Datamonitor